

Keenan Pharmacy Services
San Joaquin Valley Insurance Authority
(SJVIA)
Quarterly Key Pharmacy Benefit Metrics
Data Reviewed Through: 3rd Quarter

Quarterly Key Pharmacy Benefit Metrics

Executive Summary

SJVIA's total plan cost increased from \$5,612,568 in Q2 2022 to \$5,713,380 in Q3 2022. (1.7% increase)

- Tulare Plan Cost: \$2,611,476
- Fresno Plan Cost: \$ 3,101,903

Majority of the SJVIA members continue to fill scripts at retail.

- Retail scripts account for 98.1% of plan spend.

The Generic Dispensing Rate for Retail and Mail is consistent with previous quarters.

- Retail: 82.51%
- Retail 90: 89.64%
- Mail: 89.76%

Q3 2022 specialty plan spend had a slight increase compared to prior quarter.

Specialty Plan Costs:

- Q2 2022: \$2,604,613
- Q3 2022: \$2,646,878 (1.6% Increase from previous quarter)

Q3 2022 Specialty claims volume increased compared to prior quarter.


- 583 Scripts filed in Q2 2022
- 603 Scripts filled in Q3 2022



Quarterly Key Pharmacy Benefit Metrics

Cost Trend by Quarter

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Gross Cost	\$5,150,035	\$4,829,456	\$5,463,764	\$5,683,985	\$6,050,705	\$5,823,909	\$5,999,405	\$6,094,158
Plan Cost	\$4,769,527	\$4,443,378	\$5,072,541	\$5,284,412	\$5,672,631	\$5,424,238	\$5,612,568	\$5,713,380
Member Cost	\$380,507	\$386,078	\$391,223	\$399,573	\$378,075	\$399,670	\$386,837	\$380,778




- This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
- Gross cost = plan cost + member cost



Quarterly Key Pharmacy Benefit Metrics

Plan Cost By Channel


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Brand	\$1,213,904	\$1,148,357	\$1,130,608	\$1,193,251	\$1,214,803	\$1,173,280	\$1,133,688	\$1,150,685
Retail Generic	\$568,630	\$535,374	\$516,396	\$532,016	\$510,380	\$547,871	\$511,307	\$508,678
Retail90 Brand	\$928,860	\$885,454	\$938,130	\$978,312	\$933,622	\$957,108	\$919,343	\$906,830
Retail90 Generic	\$455,767	\$442,117	\$441,518	\$425,807	\$430,354	\$417,915	\$402,173	\$442,730
Mail Brand	\$22,821	\$22,095	\$21,536	\$24,463	\$28,460	\$32,101	\$22,046	\$28,508
Mail Generic	\$20,104	\$17,860	\$21,347	\$17,370	\$19,313	\$26,288	\$19,399	\$29,070
Specialty	\$1,559,440	\$1,392,121	\$2,003,006	\$2,113,192	\$2,535,699	\$2,269,675	\$2,604,613	\$2,646,878



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume By Channel


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Brand	3,534	2,919	3,229	3,453	4,474	3,076	2,759	2,984
Retail Generic	15,856	15,364	15,496	15,730	15,086	16,129	14,920	14,080
Retail90 Brand	942	906	891	935	859	810	799	827
Retail90 Generic	7,191	7,123	7,275	7,279	7,162	7,288	6,978	7,159
Mail Brand	35	23	28	26	33	33	23	26
Mail Generic	178	185	202	165	192	210	185	228
Specialty	507	477	539	578	572	536	583	609



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Specialty Plan Cost	\$1,559,440	\$1,392,121	\$2,003,006	\$2,113,192	\$2,535,699	\$2,269,675	\$2,604,613	\$2,646,878
Total Plan Cost	\$4,769,527	\$4,443,378	\$5,072,541	\$5,284,412	\$5,672,631	\$5,424,238	\$5,612,568	\$5,713,380
Specialty Plan Cost %	32.70%	31.33%	39.49%	39.99%	44.70%	41.84%	46.41%	46.33%



Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail GDR	81.77%	84.03%	82.76%	82.00%	77.13%	83.98%	84.39%	82.51%
Retail90 GDR	88.42%	88.72%	89.09%	88.62%	89.29%	90.00%	89.73%	89.64%
Mail GDR	83.57%	88.94%	87.83%	86.39%	85.33%	86.42%	88.94%	89.76%



Quarterly Key Pharmacy Benefit Metrics


Retail vs Mail Service Cost Trend

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Plan Cost	\$3,167,162	\$3,011,302	\$3,026,653	\$3,129,386	\$3,089,158	\$3,096,174	\$2,966,510	\$3,008,924
Mail Plan Cost	\$42,925	\$39,955	\$42,883	\$41,833	\$47,774	\$58,389	\$41,445	\$57,578
Retail Plan Cost %	98.66%	98.69%	98.60%	98.68%	98.48%	98.15%	98.62%	98.12%
Mail Plan Cost %	1.34%	1.31%	1.40%	1.32%	1.52%	1.85%	1.38%	1.88%

Plan Cost Dollars by Quarter



Plan Cost Percent by Quarter



Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: SJVIA

Top Drugs By Ingredient Cost

Based on Paid Date: 01/01/2022-09/30/2022

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	116	21	\$1,015,440.21	3,236	\$8,753.79	\$313.79
TRULICITY	ANTIDIABETICS	B	2	N	609	143	\$798,227.33	25,590	\$1,310.72	\$31.19
OZEMPIC	ANTIDIABETICS	B	2	N	623	189	\$771,605.87	25,618	\$1,238.53	\$30.12
DUPIXENT	DERMATOLOGICALS	B	2	Y	132	24	\$457,174.60	3,670	\$3,463.44	\$124.57
EMPAVELI	HEMATOLOGICAL AGENTS - MISC.	B	2	Y	11	1	\$404,589.79	308	\$36,780.89	\$1,313.60
TREMFYA	DERMATOLOGICALS	B	2	Y	26	9	\$333,950.63	1,372	\$12,844.26	\$243.40
JARDIANCE	ANTIDIABETICS	B	2	N	266	102	\$329,086.13	17,842	\$1,237.17	\$18.44
STELARA	DERMATOLOGICALS	B	2	Y	14	6	\$325,088.25	896	\$23,220.59	\$362.82
RYBELSUS	ANTIDIABETICS	B	2	N	192	65	\$274,298.65	9,360	\$1,428.64	\$29.31
ZEJULA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	12	2	\$272,453.36	360	\$22,704.45	\$756.81
TRIKAFTA	RESPIRATORY AGENTS - MISC.	B	2	Y	10	1	\$261,699.90	280	\$26,169.99	\$934.64
JANUVIA	ANTIDIABETICS	B	2	N	242	90	\$259,572.67	15,357	\$1,072.61	\$16.90
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	16	2	\$258,559.36	480	\$16,159.96	\$538.67
FARXIGA	ANTIDIABETICS	B	2	N	202	78	\$247,923.30	13,980	\$1,227.34	\$17.73
ELIQUIS	ANTICOAGULANTS	B	2	N	262	72	\$230,175.32	13,547	\$878.53	\$16.99
GENOTROPIN	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	3	Y	22	2	\$190,928.42	633	\$8,678.56	\$301.62
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	29	4	\$190,418.85	812	\$6,566.17	\$234.51
OTEZLA	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	43	7	\$186,835.29	1,290	\$4,345.01	\$144.83
LATUDA	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	2	N	87	29	\$181,344.54	3,508	\$2,084.42	\$51.69
COSENTYX SENSOREADY PEN	DERMATOLOGICALS	B	3	Y	26	4	\$172,741.88	728	\$6,643.92	\$237.28
ICLUSIG	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$157,092.80	240	\$19,636.60	\$654.55
TASIGNA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	9	1	\$153,348.49	252	\$17,038.72	\$608.53
BIKTARVY	ANTIVIRALS	B	2	Y	41	8	\$147,608.27	1,207	\$3,600.20	\$122.29
TALTZ	DERMATOLOGICALS	B	2	Y	20	6	\$144,073.62	560	\$7,203.68	\$257.27
RINVOQ	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	24	5	\$143,583.15	718	\$5,982.63	\$199.98



Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: SJVIA

Top Drugs By Claim Count

Based on Paid Date: 01/01/2022-09/30/2022

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Specialty Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	2,129	849	\$68,418.97	156,387	\$32.14	\$0.44
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	1,766	1079	\$89,254.02	40,938	\$50.54	\$2.18
LISINOPRIL	ANTHYPERTENSIVES	G	1	N	1,706	651	\$35,772.24	122,003	\$20.97	\$0.29
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	1,557	538	\$47,320.64	112,787	\$30.39	\$0.42
HYDROCODONE BITARTRATE/AC	ANALGESICS - OPIOID	G	1	N	1,341	621	\$49,953.41	24,004	\$37.25	\$2.08
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	1,237	499	\$29,717.11	84,473	\$24.02	\$0.35
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	1,213	439	\$21,455.25	85,882	\$17.69	\$0.25
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	1,157	510	\$30,656.60	74,069	\$26.50	\$0.41
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	1,101	917	\$23,155.67	20,497	\$21.03	\$1.13
AZITHROMYCIN	MACROLIDES	G	1	N	1,076	934	\$24,255.86	5,830	\$22.54	\$4.16
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	1,045	323	\$67,272.84	55,855	\$64.38	\$1.20
GABAPENTIN	ANTICONVULSANTS	G	1	N	945	377	\$34,220.73	39,415	\$36.21	\$0.87
LOSARTAN POTASSIUM	ANTHYPERTENSIVES	G	1	N	925	370	\$38,198.32	68,861	\$41.30	\$0.55
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	895	390	\$23,416.22	49,006	\$26.16	\$0.48
PREDNISONE	CORTICOSTEROIDS	G	1	N	882	673	\$7,247.10	13,603	\$8.22	\$0.53
AMOXICILLIN	PENICILLINS	G	1	N	847	758	\$7,961.13	7,413	\$9.40	\$1.07
ROSUVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	838	338	\$35,817.94	65,094	\$42.74	\$0.55
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	837	307	\$36,187.43	59,236	\$43.23	\$0.61
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	783	551	\$26,078.93	33,690	\$33.31	\$0.77
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	773	286	\$20,756.10	45,316	\$26.85	\$0.46
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	755	293	\$8,478.34	50,842	\$11.23	\$0.17
PFIZER-BIONTECH COVID-19	VACCINES	B	2	N	698	672	\$0.00	698	\$0.00	\$0.00
AMOXICILLIN/CLAVULANATE P	PENICILLINS	G	1	N	683	622	\$25,372.41	6,379	\$37.15	\$3.98
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	667	305	\$20,613.61	44,610	\$30.90	\$0.46
VITAMIN D	VITAMINS	G	1	N	644	369	\$7,231.76	42,009	\$11.23	\$0.17



Quarterly Key Pharmacy Benefit Metrics

Specialty Drug Oversight

- The management of specialty drugs is complex, as are the conditions that specialty drugs treat. With recent advances in drug therapies, patients with complex conditions now have better options to manage their conditions. While plan sponsors like the SJVIA recognize the value of these medications to their members and want to provide best-in-class drug benefits, the cost management of these drugs requires utilization management and benefit design strategies.
- Strategies implemented for the SJVIA include:
 - Prior authorization/clinical review
 - Specialty pharmacy channel management
 - Ongoing formulary review for the most cost and clinically effective medications
 - Manufacturer assistance when available
- **Recommendation: VCAP**
 - Estimated Savings :
 - Tulare - \$686,694
 - Fresno - \$1,317,522

*Net Savings



Quarterly Key Pharmacy Benefit Metrics

Rebates

- Rebates:
 - Q2 2021: \$694,892
 - Q3 2021: \$745,118
 - Q4 2021: \$700,150
 - Q1 2022: \$642,132

Rebates will be paid within 120 days at the end of the applicable quarter.

Keenan performs a clinical savings financial audit and shares the final report to the SJVIA upon completion of the end of the plan year.






Appendix

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Tulare)

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Gross Cost	\$2,126,190	\$1,964,808	\$2,236,357	\$2,340,728	\$2,560,816	\$2,581,016	\$2,722,405	\$2,791,876
Plan Cost	\$1,954,639	\$1,791,328	\$2,057,651	\$2,160,996	\$2,387,321	\$2,394,510	\$2,536,016	\$2,611,476
Member Cost	\$171,551	\$173,480	\$178,705	\$179,732	\$173,495	\$186,506	\$186,389	\$180,399




This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
 These represent total dollars spent for all products, including specialty drugs



Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Fresno)

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Gross Cost	\$3,023,845	\$2,864,648	\$3,227,408	\$3,343,256	\$3,489,889	\$3,242,893	\$3,277,000	\$3,302,282
Plan Cost	\$2,814,888	\$2,652,050	\$3,014,890	\$3,123,415	\$3,285,309	\$3,029,728	\$3,076,552	\$3,101,903
Member Cost	\$208,956	\$212,598	\$212,518	\$219,841	\$204,579	\$213,164	\$200,448	\$200,379




This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
 These represent total dollars spent for all products, including specialty drugs



Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Tulare)


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Brand	\$500,819	\$449,914	\$442,516	\$478,592	\$495,949	\$508,239	\$527,666	\$514,358
Retail Generic	\$225,339	\$209,849	\$205,842	\$212,981	\$213,580	\$215,805	\$205,827	\$202,267
Retail90 Brand	\$347,451	\$317,449	\$361,520	\$369,584	\$368,515	\$386,144	\$363,249	\$352,616
Retail90 Generic	\$174,057	\$166,146	\$174,493	\$164,873	\$171,323	\$167,179	\$167,067	\$180,661
Mail Brand	\$19,965	\$16,684	\$17,054	\$20,737	\$22,183	\$13,931	\$10,735	\$13,283
Mail Generic	\$13,230	\$10,747	\$14,971	\$11,599	\$10,633	\$16,596	\$14,393	\$17,324
Specialty	\$673,779	\$620,539	\$841,255	\$902,631	\$1,105,137	\$1,086,616	\$1,247,079	\$1,330,967



Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Fresno)


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Brand	\$713,086	\$698,442	\$688,092	\$714,659	\$718,854	\$665,042	\$606,021	\$636,327
Retail Generic	\$343,292	\$325,526	\$310,554	\$319,035	\$296,799	\$332,066	\$305,480	\$306,411
Retail90 Brand	\$581,409	\$568,006	\$576,610	\$608,728	\$565,107	\$570,964	\$556,094	\$554,214
Retail90 Generic	\$281,710	\$275,972	\$267,025	\$260,935	\$259,030	\$250,736	\$235,106	\$262,069
Mail Brand	\$2,857	\$5,411	\$4,482	\$3,726	\$6,277	\$18,170	\$11,311	\$15,224
Mail Generic	\$6,874	\$7,113	\$6,375	\$5,771	\$8,681	\$9,692	\$5,006	\$11,746
Specialty	\$885,661	\$771,582	\$1,161,751	\$1,210,561	\$1,430,562	\$1,183,059	\$1,357,534	\$1,315,911



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Tulare)


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Brand	1,367	1,148	1,184	1,322	1,728	1,235	1,224	1,296
Retail Generic	7,312	6,864	7,029	7,003	6,872	7,223	6,844	6,366
Retail90 Brand	343	307	336	347	328	314	309	308
Retail90 Generic	2,876	2,870	2,913	2,885	2,927	2,977	2,999	3,005
Mail Brand	26	15	17	18	21	14	12	11
Mail Generic	124	118	131	108	120	126	117	141
Specialty	197	190	208	223	219	228	241	261



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Fresno)


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Brand	2,167	1,771	2,045	2,131	2,746	1,841	1,535	1,688
Retail Generic	8,544	8,500	8,467	8,727	8,214	8,906	8,076	7,714
Retail90 Brand	599	599	555	588	531	496	490	519
Retail90 Generic	4,315	4,253	4,362	4,394	4,235	4,311	3,979	4,154
Mail Brand	9	8	11	8	12	19	11	15
Mail Generic	54	67	71	57	72	84	68	87
Specialty	310	287	331	355	353	308	342	348



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Tulare)


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Specialty Plan Cost	\$673,779	\$620,539	\$841,255	\$902,631	\$1,105,137	\$1,086,616	\$1,247,079	\$1,330,967
Total Plan Cost	\$1,954,639	\$1,791,328	\$2,057,651	\$2,160,996	\$2,387,321	\$2,394,510	\$2,536,016	\$2,611,476
Specialty Plan Cost %	34.47%	34.64%	40.88%	41.77%	46.29%	45.38%	49.17%	50.97%



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Fresno)


Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Specialty Plan Cost	\$885,661	\$771,582	\$1,161,751	\$1,210,561	\$1,430,562	\$1,183,059	\$1,357,534	\$1,315,911
Total Plan Cost	\$2,814,888	\$2,652,050	\$3,014,890	\$3,123,415	\$3,285,309	\$3,029,728	\$3,076,552	\$3,101,903
Specialty Plan Cost %	31.46%	29.09%	38.53%	38.76%	43.54%	39.05%	44.13%	42.42%



Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Tulare)

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail GDR	84.25%	85.67%	85.58%	84.12%	79.91%	85.40%	84.83%	83.09%
Retail90 GDR	89.34%	90.34%	89.66%	89.26%	89.92%	90.46%	90.66%	90.70%
Mail GDR	82.67%	88.72%	88.51%	85.71%	85.11%	90.00%	90.70%	92.76%




Excludes Specialty



Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Fresno)

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail GDR	79.77%	82.76%	80.55%	80.37%	74.95%	82.87%	84.03%	82.05%
Retail90 GDR	87.81%	87.65%	88.71%	88.20%	88.86%	89.68%	89.04%	88.89%
Mail GDR	85.71%	89.33%	86.59%	87.69%	85.71%	81.55%	86.08%	85.29%



Excludes Specialty




Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Tulare)

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Plan Cost	\$1,247,666	\$1,143,357	\$1,184,371	\$1,226,030	\$1,249,368	\$1,277,367	\$1,263,809	\$1,249,902
Mail Plan Cost	\$33,194	\$27,432	\$32,025	\$32,336	\$32,816	\$30,527	\$25,128	\$30,607
Retail Plan Cost %	97.41%	97.66%	97.37%	97.43%	97.44%	97.67%	98.05%	97.61%
Mail Plan Cost %	2.59%	2.34%	2.63%	2.57%	2.56%	2.33%	1.95%	2.39%

Plan Cost Dollars by Quarter



Plan Cost Percent by Quarter



Excludes Specialty




Quarterly Key Pharmacy Benefit Metrics


Retail vs Mail Service Cost Trend (Fresno)

Category	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Retail Plan Cost	\$1,919,496	\$1,867,945	\$1,842,282	\$1,903,357	\$1,839,789	\$1,818,807	\$1,702,701	\$1,759,022
Mail Plan Cost	\$9,731	\$12,523	\$10,857	\$9,497	\$14,958	\$27,862	\$16,317	\$26,971
Retail Plan Cost %	99.50%	99.33%	99.41%	99.50%	99.19%	98.49%	99.05%	98.49%
Mail Plan Cost %	0.50%	0.67%	0.59%	0.50%	0.81%	1.51%	0.95%	1.51%

Plan Cost Dollars by Quarter



Plan Cost Percent by Quarter



Excludes Specialty



Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Tulare

Top Drugs By Ingredient Cost: Tulare

Based on Paid Date: 01/01/2022-09/30/2022

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	65	12	\$565,513.51	1,806	\$8,700.21	\$313.13
EMPAVELI	HEMATOLOGICAL AGENTS - MISC.	B	2	Y	11	1	\$404,589.79	308	\$36,780.89	\$1,313.60
OZEMPIC	ANTIDIABETICS	B	2	N	329	104	\$380,808.73	12,577	\$1,157.47	\$30.28
TRULICITY	ANTIDIABETICS	B	2	N	238	57	\$296,574.25	9,472	\$1,246.11	\$31.31
TRIKAFTA	RESPIRATORY AGENTS - MISC.	B	2	Y	10	1	\$261,699.90	280	\$26,169.99	\$934.64
ICLUSIG	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$157,092.80	240	\$19,636.60	\$654.55
GILENYA	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	B	2	Y	14	2	\$136,960.00	420	\$9,782.86	\$326.10
ELIQUIS	ANTICOAGULANTS	B	2	N	142	42	\$136,827.63	8,012	\$963.57	\$17.08
JARDIANCE	ANTIDIABETICS	B	2	N	125	43	\$132,916.40	7,150	\$1,063.33	\$18.59
RINVOQ	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	23	4	\$132,785.18	690	\$5,773.27	\$192.44
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$129,279.68	240	\$16,159.96	\$538.67
RYBELSUS	ANTIDIABETICS	B	2	N	92	28	\$128,468.74	4,380	\$1,396.40	\$29.33
JANUVIA	ANTIDIABETICS	B	2	N	121	41	\$121,108.65	7,140	\$1,000.90	\$16.96
STELARA	DERMATOLOGICALS	B	2	Y	6	3	\$117,031.77	504	\$19,505.30	\$232.21
BRAFTOVI	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	3	Y	8	1	\$111,697.20	240	\$13,962.15	\$465.41
MEKTOVI	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	3	Y	8	1	\$109,589.68	240	\$13,698.71	\$456.62
FARXIGA	ANTIDIABETICS	B	2	N	88	33	\$106,429.76	6,000	\$1,209.43	\$17.74
XELJANZ XR	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	20	3	\$106,114.00	600	\$5,305.70	\$176.86
TALTZ	DERMATOLOGICALS	B	2	Y	15	3	\$104,780.81	420	\$6,985.39	\$249.48
DUPIXENT	DERMATOLOGICALS	B	2	Y	29	6	\$99,550.89	812	\$3,432.79	\$122.60
OTEZLA	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	21	3	\$91,300.28	630	\$4,347.63	\$144.92
AUBAGIO	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	B	2	Y	9	1	\$80,040.78	270	\$8,893.42	\$296.45
ZYTIGA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	7	1	\$79,562.35	210	\$11,366.05	\$378.87
TREMFYA	DERMATOLOGICALS	B	2	Y	6	2	\$77,008.20	336	\$12,834.70	\$229.19
CALQUENCE	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	3	Y	5	1	\$75,616.50	150	\$15,123.30	\$504.11

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Tulare

Top Drugs By Claim Count: Tulare

Based on Paid Date: 01/01/2022-09/30/2022

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	875	339	\$26,780.76	61,841	\$30.61	\$0.43
LISINAPRIL	ANTIHYPERTENSIVES	G	1	N	761	283	\$15,832.90	51,474	\$20.81	\$0.31
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	667	227	\$19,813.66	45,634	\$29.71	\$0.43
ALBUTEROL SULFATE HFA	ASTHMA AND BRONCHODILATOR AGENTS	G	1	N	664	387	\$33,869.74	15,512	\$51.01	\$2.18
HYDROCODONE BITARTRATE/AC	ANALGESICS - OPIOID	G	1	N	635	280	\$24,215.68	12,169	\$38.13	\$1.99
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	530	222	\$14,093.59	34,176	\$26.59	\$0.41
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	503	178	\$8,841.95	35,024	\$17.58	\$0.25
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	497	205	\$11,231.44	33,126	\$22.60	\$0.34
MONTELUKAST SODIUM	ASTHMA AND BRONCHODILATOR AGENTS	G	1	N	488	213	\$12,730.64	26,916	\$26.09	\$0.47
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	478	145	\$26,998.85	24,712	\$56.48	\$1.09
AZITHROMYCIN	MACROLIDES	G	1	N	459	399	\$10,333.83	2,559	\$22.51	\$4.04
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	437	379	\$8,473.54	7,443	\$19.39	\$1.14
LOSARTAN POTASSIUM	ANTIHYPERTENSIVES	G	1	N	427	160	\$17,034.45	30,224	\$39.89	\$0.56
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	406	150	\$4,513.67	25,829	\$11.12	\$0.17
PREDNISONE	CORTICOSTEROIDS	G	1	N	405	298	\$3,679.47	6,571	\$9.09	\$0.56
GABAPENTIN	ANTICONVULSANTS	G	1	N	402	151	\$13,102.10	16,875	\$32.59	\$0.78
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	339	139	\$9,343.18	20,598	\$27.56	\$0.45
AMOXICILLIN	PENICILLINS	G	1	N	337	307	\$3,249.82	3,027	\$9.64	\$1.07
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	330	118	\$13,410.12	22,455	\$40.64	\$0.60
OZEMPIC	ANTIDIABETICS	B	2	N	329	104	\$380,808.73	12,577	\$1,157.47	\$30.28
ROSUVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	324	118	\$13,198.32	24,330	\$40.74	\$0.54
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	322	124	\$8,386.41	18,610	\$26.04	\$0.45
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	316	211	\$10,507.60	12,900	\$33.25	\$0.81
ALPRAZOLAM	ANTI-ANXIETY AGENTS	G	1	N	304	122	\$4,802.28	7,913	\$15.80	\$0.61
SERTRALINE HCL	ANTIDEPRESSANTS	G	1	N	290	103	\$5,755.79	13,828	\$19.85	\$0.42



Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Fresno

Top Drugs By Ingredient Cost: Fresno
Based on Paid Date: 01/01/2022-09/30/2022

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
TRULICITY	ANTIDIABETICS	B	2	N	371	86	\$501,653.08	16,118	\$1,352.16	\$31.12
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	51	9	\$449,926.70	1,430	\$8,822.09	\$314.63
OZEMPIC	ANTIDIABETICS	B	2	N	294	85	\$390,797.14	13,041	\$1,329.24	\$29.97
DUPIXENT	DERMATOLOGICALS	B	2	Y	103	18	\$357,623.71	2,858	\$3,472.07	\$125.13
TREMFYA	DERMATOLOGICALS	B	2	Y	20	7	\$256,942.43	1,036	\$12,847.12	\$248.01
ZEJULA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	10	1	\$238,396.68	300	\$23,839.67	\$794.66
STELARA	DERMATOLOGICALS	B	2	Y	8	3	\$208,056.48	392	\$26,007.06	\$530.76
JARDIANCE	ANTIDIABETICS	B	2	N	141	59	\$196,169.73	10,692	\$1,391.27	\$18.35
GENOTROPIN	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	3	Y	22	2	\$190,928.42	633	\$8,678.56	\$301.62
COSENTYX SENSOREADY PEN	DERMATOLOGICALS	B	3	Y	26	4	\$172,741.88	728	\$6,643.92	\$237.28
TASIGNA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	9	1	\$153,348.49	252	\$17,038.72	\$608.53
RYBELSUS	ANTIDIABETICS	B	2	N	100	37	\$145,829.91	4,980	\$1,458.30	\$29.28
LATUDA	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	2	N	64	20	\$145,190.49	2,760	\$2,268.60	\$52.61
FARXIGA	ANTIDIABETICS	B	2	N	114	45	\$141,493.54	7,980	\$1,241.17	\$17.73
IMBRUVICA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	9	1	\$140,527.35	252	\$15,614.15	\$557.65
JANUVIA	ANTIDIABETICS	B	2	N	121	49	\$138,464.02	8,217	\$1,144.33	\$16.85
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	21	3	\$138,251.51	588	\$6,583.41	\$235.12
BIKTARVY	ANTIVIRALS	B	2	Y	38	7	\$136,641.83	1,117	\$3,595.84	\$122.33
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$129,279.68	240	\$16,159.96	\$538.67
IBRANCE	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	8	1	\$116,709.20	224	\$14,588.65	\$521.02
KESIMPTA	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	B	2	Y	11	2	\$99,284.33	308	\$9,025.85	\$322.35
OTEZLA	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	22	4	\$95,535.01	660	\$4,342.50	\$144.75
ELIQUIS	ANTICOAGULANTS	B	2	N	120	30	\$93,347.69	5,535	\$777.90	\$16.86
REXULTI	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	3	N	51	13	\$91,077.54	2,070	\$1,785.83	\$44.00
TRESIBA FLEXTOUCH	ANTIDIABETICS	B	2	N	100	39	\$89,668.31	5,819	\$896.68	\$15.41



Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Fresno

Top Drugs By Claim Count: Fresno

Based on Paid Date: 01/01/2022-09/30/2022

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	1,254	510	\$41,638.21	94,546	\$33.20	\$0.44
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	1,102	692	\$55,384.28	25,426	\$50.26	\$2.18
LISINAPRIL	ANTHYPERTENSIVES	G	1	N	945	368	\$19,939.34	70,529	\$21.10	\$0.28
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	890	311	\$27,506.98	67,153	\$30.91	\$0.41
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	740	294	\$18,485.67	51,347	\$24.98	\$0.36
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	710	261	\$12,613.30	50,858	\$17.77	\$0.25
HYDROCODONE BITARTRATE/AC	ANALGESICS - OPIOID	G	1	N	706	341	\$25,737.73	11,835	\$36.46	\$2.17
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	664	538	\$14,682.13	13,054	\$22.11	\$1.12
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	627	288	\$16,563.01	39,893	\$26.42	\$0.42
AZITHROMYCIN	MACROLIDES	G	1	N	617	535	\$13,922.03	3,271	\$22.56	\$4.26
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	567	178	\$40,273.99	31,143	\$71.03	\$1.29
GABAPENTIN	ANTICONVULSANTS	G	1	N	543	226	\$21,118.63	22,540	\$38.89	\$0.94
ROSUVASTATIN CALCIUM	ANTHYPERLIPIDEMICS	G	1	N	514	220	\$22,619.62	40,764	\$44.01	\$0.55
AMOXICILLIN	PENICILLINS	G	1	N	510	451	\$4,711.31	4,386	\$9.24	\$1.07
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	507	189	\$22,777.31	36,781	\$44.93	\$0.62
LOSARTAN POTASSIUM	ANTHYPERTENSIVES	G	1	N	498	210	\$21,163.87	38,637	\$42.50	\$0.55
PREDNISONE	CORTICOSTEROIDS	G	1	N	477	375	\$3,567.63	7,032	\$7.48	\$0.51
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	467	340	\$15,571.33	20,790	\$33.34	\$0.75
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	451	162	\$12,369.69	26,706	\$27.43	\$0.46
PFIZER-BIONTECH COVID-19	VACCINES	B	2	N	439	421	\$0.00	439	\$0.00	\$0.00
AMOXICILLIN/CLAVULANATE P	PENICILLINS	G	1	N	412	371	\$15,522.96	3,904	\$37.68	\$3.98
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	407	177	\$10,685.58	22,090	\$26.25	\$0.48
TRULICITY	ANTIDIABETICS	B	2	N	371	86	\$501,653.08	16,118	\$1,352.16	\$31.12
CYCLOBENZAPRINE HYDROCHLO	MUSCULOSKELETAL THERAPY AGENTS	G	1	N	364	201	\$6,523.59	8,675	\$17.92	\$0.75
VITAMIN D	VITAMINS	G	1	N	363	217	\$3,637.45	23,961	\$10.02	\$0.15

